209 related articles for article (PubMed ID: 37096065)
1. Meta-analysis of commonly mutated genes in leptomeningeal carcinomatosis.
Congur I; Koni E; Onat OE; Tokcaer Keskin Z
PeerJ; 2023; 11():e15250. PubMed ID: 37096065
[TBL] [Abstract][Full Text] [Related]
2. Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors.
Ozdemir Y; Yildirim BA; Topkan E
J Neurooncol; 2016 Sep; 129(2):329-35. PubMed ID: 27306442
[TBL] [Abstract][Full Text] [Related]
3. Association of MRI findings with clinical characteristics and prognosis in patients with leptomeningeal carcinomatosis from non-small cell lung cancer.
Ko Y; Gwak HS; Park EY; Joo J; Lee YJ; Lee SH; Kwon JW; Shin SH; Yoo H
J Neurooncol; 2019 Jul; 143(3):553-562. PubMed ID: 31089925
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS
J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027
[TBL] [Abstract][Full Text] [Related]
5. Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.
Gong L; Xiong M; Huang Z; Miao L; Fan Y
Lung Cancer; 2015 Sep; 89(3):268-73. PubMed ID: 26141219
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.
Arai S; Takeuchi S; Fukuda K; Taniguchi H; Nishiyama A; Tanimoto A; Satouchi M; Yamashita K; Ohtsubo K; Nanjo S; Kumagai T; Katayama R; Nishio M; Zheng MM; Wu YL; Nishihara H; Yamamoto T; Nakada M; Yano S
J Thorac Oncol; 2020 May; 15(5):752-765. PubMed ID: 31972351
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib in the treatment of leptomeningeal disease in T790M-negative, epidermal growth factor receptor-mutated non-small cell lung cancer: a case report.
Chen J; Soudy H
Chin Clin Oncol; 2019 Jun; 8(3):29. PubMed ID: 30943730
[TBL] [Abstract][Full Text] [Related]
8. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
9. Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions.
Lee DW; Lee KH; Kim JW; Keam B
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399673
[TBL] [Abstract][Full Text] [Related]
10. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.
Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM
Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497
[TBL] [Abstract][Full Text] [Related]
11. A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis.
Choi W; Cho Y; Park SY; Hwang KH; Han JY; Lee Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):213-222. PubMed ID: 32705364
[TBL] [Abstract][Full Text] [Related]
12. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid diversion and outcomes for lung cancer patients with leptomeningeal carcinomatosis.
Su YH; Chiang CL; Yang HC; Hu YS; Chen YW; Luo YH; Chen CJ; Wu HM; Lin CJ; Lee CC
Acta Neurochir (Wien); 2022 Feb; 164(2):459-467. PubMed ID: 33646444
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis.
Kim HS; Park JB; Gwak HS; Kwon JW; Shin SH; Yoo H
World J Surg Oncol; 2019 Mar; 17(1):59. PubMed ID: 30917830
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.
Ojerholm E; Lee JY; Thawani JP; Miller D; O'Rourke DM; Dorsey JF; Geiger GA; Nagda S; Kolker JD; Lustig RA; Alonso-Basanta M
J Neurosurg; 2014 Dec; 121 Suppl():75-83. PubMed ID: 25434940
[TBL] [Abstract][Full Text] [Related]
16. Leptomeningeal carcinomatosis as primary manifestation of pancreatic cancer.
Trinh VT; Medina-Flores R; Chohan MO
J Clin Neurosci; 2016 Aug; 30():124-127. PubMed ID: 26972704
[TBL] [Abstract][Full Text] [Related]
17. High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.
Nanjo S; Ebi H; Arai S; Takeuchi S; Yamada T; Mochizuki S; Okada Y; Nakada M; Murakami T; Yano S
Oncotarget; 2016 Jan; 7(4):3847-56. PubMed ID: 26716903
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with recurrent leptomeningeal metastases in patients with EGFR-mutated non-small-cell lung cancer.
Watanabe H; Okauchi S; Miyazaki K; Satoh H; Hizawa N
Pol Arch Intern Med; 2019 Nov; 129(11):836-838. PubMed ID: 31456585
[No Abstract] [Full Text] [Related]
19. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
Wang M; Zhu F; Luo N; Li M; Qi Y; Wang M
Medicine (Baltimore); 2021 Nov; 100(44):e27727. PubMed ID: 34871271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
